- Research Article
- 10.1182/blood-2025-6929
Acute Myeloid Leukemia: Diagnosis and treatment at a tertiary center in cochabamba - Bolivia.
- Nov 03, 2025
- Blood
- Veronica Saavedra + 7 more +7
Publications from 2021 to 2026
Showing 10 of 108 papers
Acute Myeloid Leukemia: Diagnosis and treatment at a tertiary center in cochabamba - Bolivia.
Risk of Future Hemorrhage From Unruptured Brain Arteriovenous Malformations
Annual rates of first intracranial hemorrhage (ICH) from unruptured brain arteriovenous malformations (AVMs) are often quoted as 2% to 4% in clinical practice. Precise estimates and risk factors are unavailable to inform treatment decisions. To provide estimates of rates and risk factors for first ICH in a large cohort study of unruptured brain AVMs. The Multicenter Arteriovenous Malformation Research Study (MARS) included data from 9 cohorts, each contributing 100 or more unruptured brain AVMs. The study was conducted from 2017 to 2023 with retrospective and prospective data collection for existing cohorts and/or new recruitment. This was an international study (2 population-based and 7 referral-based cohorts) that included participants diagnosed with an unruptured brain AVM. Demographic, clinical, and angiographic characteristics. The primary outcome was time to first ICH after diagnosis of unruptured brain AVM. Data were collected using standardized definitions; missing data were imputed. Cox regression analysis was performed, censoring at first brain AVM treatment, death, or last visit, and allowing baseline hazards to vary by cohort. A total of 3225 individuals were eligible for participation in this study. After 195 exclusions, 3030 participants (median [IQR] age, 38 [25-50] years; 1524 female [50.3%]) were included. Among 2989 participants with unruptured brain AVMs, 1333 (45%) presented with seizure. The median (IQR) maximal brain AVM diameter was 3.1 (2.2-4.4) cm, 248 of 2466 AVMs (10%) had exclusively deep venous drainage, 297 of 2690 (11%) were in supratentorial deep or cerebellar locations, and 457 of 2440 (19%) had associated arterial aneurysms. First ICH occurred in 159 participants over 11 339 person-years of follow-up for an ICH rate of 1.40 (95% CI, 1.20-1.64) per 100 person-years. Significant independent risk factors included (1) increasing age category at diagnosis (hazard ratio [HR], 0.87; 95% CI, 0.53-1.41 for those aged 20 to 39 years; HR, 1.23; 95% CI, 0.74-2.04 for those aged 40 to 59 years; and HR, 2.01; 95% CI, 1.14-3.57 for those aged 60 years vs younger than 20 years; P = .008), (2) presence of associated aneurysms (HR, 1.66; 95% CI, 1.06-2.59; P = .03), and (3) cerebellar or supratentorial deep location (HR, 1.87; 95% CI, 1.16-3.00; P = .01). The annual ICH rate from unruptured brain AVM was lower than that commonly cited in clinical practice. Increasing age, associated arterial aneurysms, and cerebellar or supratentorial deep brain AVM location were associated with risk of first ICH. These results may be used to counsel patients about the natural history of unruptured brain AVMs.
Read moreTCT-1185 A Novel Technique for Commissural Alignment of Balloon-Expandable Transcatheter Aortic Valve Replacement: The SBCA Experience
Japanese encephalitis presenting as transverse myelitis in a traveller to Indonesia: a cautionary note for surfers.
Population-level analysis of circadian variations in blood cells
ABSTRACT Knowledge of circadian rhythms is crucial in laboratory medicine to understand disease pathophysiologies and improve patient diagnoses and treatments. Here, we aim to determine whether circadian variations in blood cells are present at a population level and assess whether these rhythms are consistent with those reported previously in individuals. In a retrospective observational study we employed blood sample data analyzed at a local emergency laboratory over a period of 7 years, including the number of blood cells, time of sample collection, and patient age (between 18 and 85 years). Data showing cell counts outside the normal range were excluded, yielding a dataset consisting of 189,635 individual data points from 164,982 different patients. Records were grouped into 30-min intervals to determine their temporal distribution and average wave. We detected a circadian rhythm in all studied blood cell types (p < 0.01), with all except neutrophils peaking during the resting phase and exhibiting minimum values during the activity phase. Results were confirmed through parametric and nonparametric analyses. To the best of our knowledge, this is the first report of a significant circadian rhythm in blood cells at population level. The observed temporal variations at population level are comparable to those previously described for individuals.
Read moreEvaluation of the effectiveness and safety of avapritinib in real-world Spanish cases with gastrointestinal stromal tumor and D842V-PDGFRA mutation.
Gastrointestinal stromal tumors (GISTs) are the most common sarcoma subtype. Patients with unresectable or metastatic GISTs harboring the D842V mutation in the PDGFRA gene have a poor prognosis due to intrinsic resistance to imatinib and all other approved tyrosine kinase inhibitors. Avapritinib, targeting this mutation, is the first agent approved for patients with unresectable or metastatic GIST that have the PDGFRA D842V mutation. This study assesses the effectiveness and safety of avapritinib in real-world clinical scenarios involving Spanish patients with this mutation. The AVARWE study is a descriptive, retrospective, multicenter observational study of 21 patients treated with avapritinib across 13 Spanish centers from June 9, 2023, to December 18, 2023. Data collected included patient demographics, disease characteristics, treatment history, and response rates based on RECIST criteria. The main outcomes, progression-free survival (PFS) and overall survival (OS), were measured, with safety assessed through adverse events documentation according to CTCAE criteria. Median PFS 35.6 was months and median OS was 42.2 months, with survival rates at 1, 5, and 3 years demonstrating avapritinib effectiveness. The objective response rate was 76.2% for partial response and 4.8% for complete response. Avapritinib enabled surgical intervention in previously unresectable cases and was generally well-tolerated, with manageable adverse events. Avapritinib extends PFS and OS among patients with PDGFRA D842V-mutant GIST in real-world practice, mirroring pivotal trial outcomes. Its substantial activity supports its use as a first-line therapy for this subgroup. The manageable safety profile reinforces avapritinib viability for routine use. Given the rarity of these cases, it is advised to consult sarcoma-expert units.
Read moreCase Report: Atrial baffles of pulmonary and systemic veins for the anatomic and physiologic repair of left atrial isomerism heterotaxy—pre- and post-operative three-dimensional reconstructions of two mirror-image pediatric hearts
Intra-atrial baffles of pulmonary and systemic venous flows are relatively rarely used but are important surgical procedures for late-presenting d-transposition of the great arteries (D-TGA) or heterotaxy with anomalous venous connections. Atrial baffle surgery is employed less frequently today due to the advent of the arterial switch procedure. Two children presented with mirror-image venous connections in polysplenic heterotaxy and underwent intra-atrial baffle biventricular repairs. Both cases had ipsilateral pulmonary venous connections, interrupted inferior vena cava with azygous continuation, and concordant ventriculo-arterial connections. Furthermore, a single superior vena cava receiving the azygous and hepatic veins connected to the atrium contralateral to the sub-pulmonary right ventricle was present in both cases. Volumetric cardiac imaging using computed tomography and magnetic resonance imaging allowed for the creation of three-dimensional (3D) model reconstructions for pre-operative surgical planning and postoperative assessment of the atrial baffle pathways. The 3D model reconstructions presented here provide improved visualization and understanding of complex surgical atrial baffles.
Read moreVirtual learning during medical school may inadequately prepare students for general surgical residency
Impact of COVID-19 on post-treatment breast cancer surveillance and outcomes.
e23114 Background: Little is known about the impact of the COVID-19 pandemic on post-treatment surveillance for patients diagnosed with breast cancer. Disruptions in recommended cancer surveillance screening to detect progression or recurrence could impact long-term outcomes. In this study, we compared use of recommended surveillance screening in pre- and post-COVID time periods for patients diagnosed with breast cancer within a large integrated healthcare system, Kaiser Permanente Southern California (KPSC). We also evaluated detection of breast cancer recurrence or progression. Methods: We identified patients in post-treatment surveillance for early-stage breast cancer in two time periods, pre-COVID and post-COVID. Pre-COVID included patients diagnosed 01/01/2015-12/31/2016 with 2 years of follow-up time through 12/31/2019; post-COVID included patients diagnosed 06/01/2018-05/31/2020 with 2 years of follow-up time through 05/31/2023. Eligible patients were diagnosed with stage 0-II breast cancer and received curative surgery. We excluded patients with multiple cancers, and those who disenrolled from the health plan, died, or were referred to hospice within the 2-year surveillance period. Based on NCCN guidelines, we identified the proportion of patients who underwent annual breast imaging during each year of the surveillance period. A log Poisson model examined the association between imaging and COVID period; covariates included patient age, race/ethnicity, cancer stage, treatment, and comorbidity score. We identified cancer recurrence or progression using diagnostic, treatment, and imaging codes. Results: We identified 3,369 pre-COVID patients and 3,925 post-COVID patients; groups were similar (Table 1). A significantly smaller proportion of post-COVID patients received surveillance screening (first surveillance year: 85% in the pre-COVID group vs. 77% post-COVID, p = 0.001; second year: 83% vs. 80%, p = 0.01). Patients were 4% less likely to receive imaging post-COVID compared to pre-COVID (adjusted OR 0.96, 95% CI: 0.94-0.98). Similar percentages of patients had breast cancer recurrence or progression in the pre-COVID (2.7%) and post-COVID (2.5%) periods (p-value = 0.44). Conclusions: Fewer post-treatment breast cancer patients received recommended annual breast cancer screening for surveillance in the post-COVID period compared to pre-COVID, but breast cancer recurrence or progression was similar between groups. Given the less frequent surveillance in the post-COVID period, cancer recurrence and progression should be evaluated over 5- and 10-year periods as data become available. [Table: see text]
Read morePatient Outcomes After Mechanical Suction Thrombectomy for Pulmonary Embolism at a Community Hospital in Santa Barbara: A Retrospective Study